Receptor Decoy Peptide Lowers Blood Pressure

Minimal interstitial fibrosis in male Zucker lean rat kidney (25-weeks old). From the cited paper.

Adult type 2 diabetics are at very high risk of obesity-associated hypertension, where the end result can be as grave as heart failure. The systems involved in the human body regarding these conditions can be complex, but scientists have identified cases of stroke and refractory hypertension that harbored increased plasma IgG, 5-hydroxytryptamine 2A receptor (5-HT2AR)-targeting autoantibodies.

Serotonin 2A-Receptor Decoy Peptide Lowers Blood Pressure

The goal was to test whether a decoy receptor peptide could lower blood pressure in an animal model of obesity-associated hypertension. The team developed the decoy receptor peptide, SCLLADDN (Sertuercept), and LifeTein synthesized it successfully for the project. Using Zucker hypertensive diabetic fatty rats as the model, the team proved their theory.

Results showed after implementing the decoy receptor peptide, acute and long-lasting significant systolic and diastolic blood pressure-lowering occurred within the rat models. This followed through without any long-term side effects after chronic administration. Hopefully, these results are fruitful in later applications and the same peptide can be used to help significantly lower blood pressure in humans afflicted with type 2 diabetes as well.

Zimering MB. A Serotonin 2A-Receptor Decoy Peptide Potently Lowers Blood Pressure in Male Zucker Diabetic, Fatty, Hypertensive Rats. Endocrinology, Diabetes and Metabolism Journal. 2021 Aug;5(2). DOI: 10.31038/edmj.2021523. PMID: 35035793; PMCID: PMC8759716.

Our Services:

COVID-19 Services & Products

Custom Antibody Services

Rush Peptide Synthesis

Peptide Nucleic Acids (PNAs)

Custom Peptide Synthesis Services

Gene Synthesis Service

Custom Chemical Synthesis

Other Posts:

LifeTein’s Synthetic RBD Develops COVID Multiplex Assay

Gallium Nanoparticles as Inhibitors of Alzheimer’s Peptide

LifeTein’s CPPs and Nanomaterial Internalization

HERV Peptide Derivatives as Biomarkers